Your session is about to expire
← Back to Search
CAR-Macrophages + Pembrolizumab for HER2 Positive Cancer
Study Summary
This trial is testing a new cancer treatment involving CAR macrophages (a type of white blood cell) and HER2 overexpressing solid tumors (a type of cancer).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received an organ or tissue transplant from another person.My cancer is HER2-positive, has returned or spread, and cannot be cured with available treatments.I am fully active or can carry out light work.I have an immune system disorder or I'm on long-term steroids or other drugs that weaken my immune system.You have a severe allergic reaction to pembrolizumab or any of its ingredients.My HER2-positive cancer has not responded to standard treatments.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.My breast or stomach cancer did not respond to previous HER2 treatments.My bone marrow and organs are working well.Your heart's pumping ability is less than 50% according to a heart imaging test.I do not have HIV, active hepatitis B or C.I am willing and able to have a biopsy.I have or had lung inflammation that needed steroids.My HER2-positive cancer has not responded to standard treatments.I have untreated brain metastases or cancer in my brain's lining.
- Group 1: CT-0508 in Combination with Pembrolizumab
- Group 2: 89[Zr]radiolabeled CT-0508
- Group 3: Group 1 and Group 2
- Group 4: Intraperitoneal Administration
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is CT-0508 a viable option for risk mitigation?
"The safety of CT-0508 was largely unknown, so it received a score of 1. This is because this trial is in its early stages and there has been scant evidence to suggest efficacy or lack thereof."
Is participation in this study currently available to potential subjects?
"Affirmative. Clinicaltrials.gov exhibits that the medical experiment, which was first put online on February 2nd 2021, is actively enrolling participants. A total of 18 individuals must be recruited from 5 sites to complete this research endeavour."
How many sites are offering the trial administration?
"This clinical trial is enrolling patients at Abramson Cancer Center in Philadelphia, Tennessee Oncology/Sarah Cannon Research Institute in Nashville, and M D Anderson Cancer Center in Houston. Additionally, there are 5 other sites participating."
How many participants are being observed during this experiment?
"To join this medical trial, 18 suitable candidates need to be recruited. These individuals can come from two separate locations: Abramson Cancer Center in Philadelphia and the Sarah Cannon Research Institute located in Nashville, Tennessee."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger